New rapid blood test could slash unnecessary antibiotic use in sepsis

NCT ID NCT06069206

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a rapid blood test (T2Bacteria Panel) that identifies bacteria directly from blood, compared to standard blood cultures that take 1-3 days. Researchers wanted to see if using this test could help doctors stop unnecessary vancomycin (a strong antibiotic) sooner in 500 adults with suspected sepsis. The goal is to reduce side effects and antibiotic resistance while still treating infections effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
T2Bacteria Panel (direct-from-blood bacterial test)
What this could lead to
If successful, this test could help doctors stop unnecessary antibiotics sooner, reducing side effects and antibiotic resistance.
What could go wrong
This is a single-center trial with 500 patients, so results may not apply everywhere. The test may not always be accurate, and faster antibiotic changes might not improve overall outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLOODSTREAM INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.